The role of breast fine needle aspiration during and post‐COVID‐19 pandemic: A fast and safe alternative to needle core biopsy

Gomes, D; Schmitt, Fernando

doi:10.1111/cyt.12894

Cited by 7 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TCB has become one of the best methods in terms of reliability, accuracy, and reproducibility in the diagnosis of breast lesions. Pinto D. et al in their study, claimed that FNABs could be an accurate and valuable method in symptomatic breast lesions in the period of COVID-19 in terms of both being fast and requiring less personnel and less invasive 15 .…”

Section: Discussionmentioning

confidence: 99%

The impact of the COVID-19 pandemic on the breast cancer diagnosis process

ALTINTAŞ

Bayrak

2022

Cukurova Medical Journal

View full text Add to dashboard Cite

Purpose: The primary aim of thşis study was to evaluate difference in the number of patients with tru-cut biopsies to diagnose breast lesions between non-pandemic and pandemic periods. Materials and Methods: In this study, the nonpandemic period and the pandemic period were compared, the periods for the pandemic times, between March 1, 2018, and 29 February 2020, and for the nonpandemic period, 1 March 2020 to 12 March 2022 to 12 March 2022. In each period, we have included all the tru-cut biopsies for suspected breast cancer. During the pandemic and non-pandemic period, the number of tru-cut biopsies BI-RADS and histopathological findings of the patients who experienced tru-cut biopsies were compared. Results: The number of tru-cut biopsies performed during the nonpandemic and pandemic period was similar (1596, 1599). In the pandemic period, tru-cut biopsy histopathologic reports revealed that benign and high-risk cases decreased statistically, while invasive carcinoma cases increased by 1.9 (95% CI 1.6-2.2) times. During the pandemic period, US-guided BI-RADS 3 and BI-RADS 4a cases decreased statistically significantly, BBI-RADS 4b cases increased 1.4 (95% CI 1.1-2.2) times, BI-RADS 4c cases 1.7 (95% CI 1.2-2.2), BI-RADS 5 cases increased 2.1 (95% CI 1.4-3.1) times Conclusion: There was no significant change in tru-cut biopsy numbers compared to the period of the pandemic and the non-pandemic period. However, the stage of the cancers captured during the period of the pandemic was higher.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of the COVID-19 pandemic on the breast cancer diagnosis process

ALTINTAŞ

Bayrak

2022

Cukurova Medical Journal

View full text Add to dashboard Cite

show abstract

“…Vigliar et al reported a relative increase in the percentage of breast nodule FNAs during the COVID‐19 pandemic compared to the same period in 2019 (11.7% and 3.7%, respectively; P = .002) 8 . FNAs showed important advantages compared to more invasive core needle biopsies 14 . In particular, in a period with a limited number of personnel, FNAs are more cost‐effective and quicker to perform than core needle biopsies 14 .…”

Section: The Effect Of Covid‐19 On Cytopathology Diagnostic Activitymentioning

confidence: 99%

“…FNAs showed important advantages compared to more invasive core needle biopsies 14 . In particular, in a period with a limited number of personnel, FNAs are more cost‐effective and quicker to perform than core needle biopsies 14 . In addition, cytological material is suitable for ancillary techniques 43 .…”

Section: The Effect Of Covid‐19 On Cytopathology Diagnostic Activitymentioning

confidence: 99%

“…In addition, most non‐urgent elective medical procedures, including those related to cytopathological screening activities, were postponed 8,9 . In this dramatic scenario, it is not surprising that cytopathology activities have also undergone major changes 10‐15 . Here, we briefly review how the COVID‐19 outbreak impacted on cytopathology laboratories in terms of biosafety and diagnostic activities, including molecular cytopathology testing.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Juggling the COVID‐19 pandemic: A cytopathology point of view

et al. 2020

View full text Add to dashboard Cite

Since its first identification in China at the end of 2019, severe acute respiratory syndrome coronavirus 2 has rapidly spread all over the world, becoming an international healthcare emergency. In the era of coronavirus disease‐2019 (COVID‐19), several aspects of normal life, including those related to the medical activities, have been radically changed. Extraordinary measures have been adopted by different nations to cope with the rapid diffusion of COVID‐19 all over the world. In hospitals, careful attention has been paid to manage infected patients with a possible detrimental effect for patients affected by other diseases. As with other medical fields, cytopathology laboratories have also drastically modified their activities to cope with the COVID‐19 healthcare emergency. Here, the main effects of COVID‐19 pandemic on the routine practice of cytopathology are summarised, focusing on the prioritisation policy adopted by cytopathologists worldwide.

show abstract

“…At this moment, many countries around the world are in lockdown again; although the reduction in cases is less dramatic this time, ongoing constraints on health services overburdened by COVID‐19 will result in delays and increased waiting lists for vitally important diagnostic and therapeutic procedures. Cytopathology can play a role in alleviating the backlog of patients, providing a quick and cost‐effective diagnosis, as for example in breast fine needle aspiration 14 …”

mentioning

confidence: 99%